Aarey Drugs & Pharmaceuticals Share Price | Aarey Drugs & Pharmaceuticals Stock Screener
AAREYDRUGS
Pharmaceuticals
Share Price NSE
₹95.19
▲
3.15 (3.42%)
Share Price BSE
₹87.85
▲
1.72 (2.00%)
As of April 28, 2026, the Aarey Drugs & Pharmaceuticals share price (NSE: AAREYDRUGS) is ₹95.19 on NSE and ₹87.85 on BSE, up 3.42% from the previous close, with shares trading between ₹90.55 and ₹96.00, and a 52-week range of ₹50.75–₹95.19.
Analyse Aarey Drugs & Pharmaceuticals share price performance and track historical price performance.
Use the Aarey Drugs & Pharmaceuticals stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Aarey Drugs & Pharmaceuticals Market Cap
₹240.60 Cr.
AAREYDRUGS P/E Ratio (TTM)
61.52
Aarey Drugs & Pharmaceuticals P/B Ratio
1.62
EPS (TTM)
₹1.39
Dividend Yield
-
Debt to Equity
0.24
AAREYDRUGS 52 Week High
₹95.19
Aarey Drugs & Pharmaceuticals 52 Week Low
₹50.75
Operating Margin
2.00%
Profit Margin
0.85%
AAREYDRUGS Revenue (TTM)
₹472.00
EBITDA
₹7.00
Net Income
₹4.00
Total Assets
₹291.00
Total Equity
₹139.00
Aarey Drugs & Pharmaceuticals Share Price Chart
Screen Aarey Drugs & Pharmaceuticals share price with an interactive chart. Analyse AAREYDRUGS price trends and volatility across different timeframes.
Aarey Drugs & Pharmaceuticals Company Profile - Fundamental Screener
Screen Aarey Drugs & Pharmaceuticals company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for AAREYDRUGS shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE198H01019
Aarey Drugs & Pharmaceuticals Balance Sheet Screener
Screen AAREYDRUGS balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 291 | 303 | 291 | 245 | 233 | 194 | 146 | 170 | 143 | 125 |
| Current Assets | 266 | 283 | 271 | 219 | 218 | 181 | 133 | 157 | 130 | 117 |
| Fixed Assets | 16 | 13 | 14 | 15 | 14 | 12 | 12 | 12 | 12 | 8 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 3 | 4 | 6 | 5 | 3 | 2 | 2 | 1 | 2 | 0 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 139 | 133 | 117 | 114 | 99 | 92 | 87 | 80 | 49 | 37 |
| Share Capital | 29 | 28 | 25 | 25 | 23 | 23 | 23 | 23 | 18 | 17 |
| Reserves & Surplus | 105 | 100 | 87 | 86 | 73 | 67 | 61 | 55 | 30 | 20 |
Aarey Drugs & Pharmaceuticals Income Statement Screener - Profit & Revenue Analysis
Screen Aarey Drugs & Pharmaceuticals income statement and profit fundamentals.
Analyze AAREYDRUGS quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Aarey Drugs & Pharmaceuticals share price evaluation.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 472 | 484 | 403 | 422 | 495 | 355 | 307 | 359 | 353 | 399 | 249 | 216 |
| Expenses | 465 | 471 | 391 | 411 | 481 | 344 | 297 | 347 | 342 | 386 | 245 | 212 |
| EBITDA | 7 | 13 | 11 | 11 | 14 | 12 | 10 | 12 | 11 | 13 | 4 | 4 |
| Operating Profit % | 2.00% | 1.00% | 1.00% | 2.00% | 2.00% | 1.00% | 1.00% | 2.00% | 2.00% | 2.00% | 0.00% | 1.00% |
| Depreciation | 3 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Interest | 5 | 5 | 4 | 3 | 2 | 2 | 2 | 2 | 2 | 4 | 2 | 2 |
| Profit Before Tax | 5 | 6 | 5 | 6 | 10 | 8 | 7 | 9 | 8 | 8 | 2 | 1 |
| Tax | 2 | 2 | 1 | 2 | 4 | 2 | 1 | 2 | 2 | 3 | 1 | 0 |
| Net Profit | 4 | 4 | 5 | 4 | 7 | 7 | 6 | 7 | 6 | 6 | 1 | 1 |
| EPS | 1.39 | 1.42 | 1.84 | 1.49 | 2.72 | 2.79 | 2.48 | 2.80 | 2.64 | 3.03 | 0.77 | 0.65 |
Aarey Drugs & Pharmaceuticals Cash Flow Screener - Liquidity Fundamentals
Screen AAREYDRUGS cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 10 | -3 | -1 | 1 | 6 | 3 | 1 | -20 | 1 | 6 |
| Investing Activities | -6 | -2 | 0 | -3 | -3 | -1 | -1 | -1 | -5 | -3 |
| Financing Activities | -5 | 6 | 1 | 2 | -3 | -2 | -3 | 23 | 4 | -2 |
| Net Cash Flow | 0 | 1 | 1 | -1 | 0 | 0 | -3 | 2 | -1 | 2 |
Aarey Drugs & Pharmaceuticals Shareholding Pattern Screener
See Aarey Drugs & Pharmaceuticals shareholding pattern with promoter, FII, and DII holdings.
Check Aarey Drugs & Pharmaceuticals promoter holding and ownership changes for AAREYDRUGS on TickJournal.
| Item | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Mar | 2024-Jun | 2024-Sept |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 37.71% | 39.06% | 44.80% | 44.80% | 44.80% | 45.28% | 45.28% | 45.44% |
| FII Holding | 4.18% | 3.86% | 1.13% | 1.97% | 2.34% | 3.40% | 3.40% | 2.75% |
| DII Holding | 1.62% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 43.71% | 45.40% | 47.01% | 46.60% | 45.79% | 47.14% | 44.51% | 47.56% |
| Other Holding | 12.78% | 11.69% | 7.06% | 6.63% | 7.07% | 4.18% | 6.82% | 4.25% |
| Shareholder Count | 14,188 | 14,063 | 14,897 | 15,796 | 16,257 | 16,821 | 16,179 | 16,676 |
Aarey Drugs & Pharmaceuticals Share Dividend Screener - Share Yield Analysis
Check Aarey Drugs & Pharmaceuticals dividend history with payout and yield data.
View Aarey Drugs & Pharmaceuticals dividend details including ex-dates and amounts for AAREYDRUGS stock.
Aarey Drugs & Pharmaceuticals Stock Index Membership
See which indices include Aarey Drugs & Pharmaceuticals stock.
Check AAREYDRUGS index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Aarey Drugs & Pharmaceuticals Market Events Screener - Corporate Actions
Get Aarey Drugs & Pharmaceuticals corporate actions including splits, bonuses, and buybacks.
Check Aarey Drugs & Pharmaceuticals stock events that may affect AAREYDRUGS share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Annual General Meeting | NA | -0.04% | ||
| Annual General Meeting | NA | 10.28% | ||
| 2026-05-30 | 2026-05-30 | Quarterly Result Announcement | NA | -3.74% |
| 2026-02-11 | 2026-02-11 | Quarterly Result Announcement | NA | 0.65% |
| 2025-11-13 | 2025-11-13 | Quarterly Result Announcement | NA | -0.63% |
| 2025-08-13 | 2025-08-13 | Quarterly Result Announcement | NA | -3.09% |
| 2025-05-30 | 2025-05-30 | Quarterly Result Announcement | NA | 1.28% |
| 2025-02-14 | 2025-02-14 | Quarterly Result Announcement | NA | -4.40% |
| 2024-11-14 | 2024-11-14 | Quarterly Result Announcement | NA | -8.16% |
| 2023-12-29 | 2023-12-29 | Annual General Meeting | NA | 10.77% |
| 2023-12-29 | 2023-12-29 | Extraordinary General Meeting | NA | 10.77% |
Aarey Drugs & Pharmaceuticals Competitors Screener - Peer Comparison
Screen AAREYDRUGS competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 457,025 | 39.71 | 58,220 | 6.38% | 11,565 | 69.58 |
| Divis Laboratories | 179,377 | 69.89 | 10,560 | 8.73% | 2,520 | 55.41 |
| Torrent Pharmaceuticals | 161,381 | 75.43 | 13,886 | 20.34% | 2,138 | 70.39 |
| Cipla | 117,800 | 30.51 | 29,045 | 2.24% | 3,870 | 66.80 |
| Zydus Life Science | 114,771 | 22.41 | 26,720 | 13.65% | 5,242 | 66.88 |
| Dr Reddys Laboratories | 114,692 | 27.60 | 35,059 | 3.90% | 4,158 | 67.04 |
| Lupin | 113,211 | 21.14 | 27,488 | 19.98% | 5,345 | 71.73 |
| Mankind Pharma | 104,430 | 53.93 | 14,278 | 12.03% | 1,750 | 60.79 |
| Aurobindo Pharma | 93,240 | 26.86 | 33,385 | 3.21% | 3,376 | 70.76 |
| Laurus Labs | 83,262 | 93.55 | 6,868 | 22.01% | 890 | 71.63 |
Aarey Drugs & Pharmaceuticals Company Announcements - News Screener
Screen AAREYDRUGS latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-06-28 | Closure of Trading Window | - |
| 2026-06-02 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-05-30 | Compliances-Reg.24(A)-Annual Secretarial Compliance | - |
| 2026-05-30 | Statement Of Deviation & Variation | - |
| 2026-05-30 | Audited Standalone Financial Results Of The Company For The Fourth Quarter And Year Ended March 31 2026 | - |
| 2026-05-30 | Board Meeting Outcome for Outcome Of Board Meeting Held On Saturday 30Th May 2026 | - |
| 2026-05-29 | Board Meeting Intimation for Regarding Postponement And Re-Schedule Of Board Meeting | - |
| 2026-05-25 | Board Meeting Intimation for Approving The Audited Financial Results For The Quarter And Year Ended March 31 2026 | - |
| 2026-04-14 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-03-26 | Closure of Trading Window | - |
| 2026-02-14 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-02-12 | Board Comments On The Fine Levied By The Exchange | - |
| 2026-02-11 | Unaudited Financial Results For The Quarter Ended 31St December 2025 | - |
| 2026-02-11 | Board Meeting Outcome for Outcome Of Board Meeting Held On Today I.E 11Th February 2026. | - |
| 2026-02-04 | Board Meeting Intimation for Board Meeting Intimation | - |
| 2026-01-14 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2025-12-30 | Closure of Trading Window | - |
| 2025-11-15 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2025-11-13 | Unaudited Financial Results For The Quarter & Half Year Ended On 30Th Sept 2025 | - |
| 2025-11-13 | Board Meeting Outcome for Outcome Of Board Meeting Held On 13Th November 2025 | - |